Hologic (NASDAQ:HOLX)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a report released on Tuesday, Marketbeat.com reports. They presently have a $48.00 target price on the medical equipment provider’s stock, up from their prior target price of $46.00. Needham & Company LLC’s price objective points to a potential upside of 14.70% from the company’s current price.

A number of other research firms have also recently weighed in on HOLX. Piper Jaffray Companies reissued a “buy” rating and set a $48.00 price objective on shares of Hologic in a report on Thursday, November 9th. Royal Bank Of Canada reissued a “sector perform” rating and set a $45.00 price objective (down previously from $50.00) on shares of Hologic in a report on Wednesday, August 9th. Barclays reaffirmed an “equal weight” rating and issued a $51.00 target price (down from $53.00) on shares of Hologic in a report on Wednesday, August 9th. Jefferies Group reaffirmed a “buy” rating and issued a $44.00 target price (down from $49.00) on shares of Hologic in a report on Tuesday, October 10th. Finally, BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $47.38.

Hologic (NASDAQ HOLX) traded up $1.00 during mid-day trading on Tuesday, reaching $41.85. 5,889,100 shares of the company’s stock were exchanged, compared to its average volume of 2,769,580. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. Hologic has a 12 month low of $35.76 and a 12 month high of $46.80. The firm has a market capitalization of $11,261.67, a PE ratio of 20.22, a P/E/G ratio of 1.97 and a beta of 0.95.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. During the same quarter last year, the company earned $0.52 earnings per share. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. equities analysts predict that Hologic will post 2.12 EPS for the current year.

In other news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The disclosure for this sale can be found here. Insiders have sold a total of 35,972 shares of company stock valued at $1,385,977 in the last ninety days. Corporate insiders own 0.79% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Grove Bank & Trust grew its holdings in shares of Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 1,535 shares during the period. Hall Laurie J Trustee grew its holdings in shares of Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares during the period. Commonwealth Bank of Australia grew its holdings in shares of Hologic by 31.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 600 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in shares of Hologic during the 2nd quarter worth about $191,000. Finally, National Asset Management Inc. purchased a new stake in shares of Hologic during the 2nd quarter worth about $203,000. 98.09% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/needham-company-llc-boosts-hologic-holx-price-target-to-48-00.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.